Treatment of an Acquired Coagulopathy with Recombinant Activated Factor VII in a Damage-Control Patient

From: Military Medicine | Date: April 1, 2005| Author: Hoots, Keith; Moore, Fredrick A; Holcomb, John B | Copyright information

Recombinant activated factor VII is commonly used for the treatment of hemophiliac patients with inhibitors and has been studied for use in trauma. We report the use of recombinant activated factor VII for a male patient who was injured in a motor vehicle accident. We also summarize the animal studies and clinical trials that have been reported.

Introduction

Recombinant activated factor VII (rFVIIa) is a Food and Drug Administration-licensed drug that has been approved and is co...

Read all of this article with a FREE trial to HighBeam Research

Related newspaper, magazine, and journal articles from HighBeam Research

Recombinant activated factor VII for exsanguinating haemorrhage post bilateral lung transplantation for extra-corporeal lung support-dependent respiratory failure
Anaesthesia and Intensive Care ; SUMMARY Following three weeks of extracorporeal lung support for acute respiratory distress syndrome, a 15-year-old male underwent bilateral lung transplantation. This procedure was complicated by massive postoperative haemorrhage. The administration of recombinant activated Factor VII was
Use of Recombinant Activated Factor VII After Axillofemoral Bypass Grafting
Anaesthesia and Intensive Care ; SUMMARY Recombinant activated factor VII (rFVIIa) is a powerful prohaemostatic agent that theoretically predisposes to thrombosis after peripheral vascular surgery. He report the use of rFVII to reduce bleeding in a patient alter axillofemoral bypass grafting for ruptured aorto-iliac
Treatment of an Acquired Coagulopathy with Recombinant Activated Factor VII in a Damage-Control Patient
Military Medicine ; Recombinant activated factor VII is commonly used for the treatment of hemophiliac patients with inhibitors and has been studied for use in trauma. We report the use of recombinant activated factor VII for a male patient who was injured in a motor vehicle accident. We also summarize the animal
Treating Traumatic Bleeding in a Combat Setting: Possible Role of Recombinant Activated Factor VII
Military Medicine ; Introduction Recombinant activated factor VIl (rFVlIa) has been shown to be an effective treatment for bleeding episodes in a variety of coagulation and platelet disorders. The use of rFVIIa in trauma among patients without preexisting coagulopathy has not been approved by the Food and Drug
Treatment of Bleeding in Severe Hemorrhagic Pancreatitis with Recombinant Factor VIIa
The American Surgeon ; Recombinant factor VIIa (rFVIIa) has been used to treat bleeding complications in patients with hemophilia. It acts at the site of vessel injury, forming a complex with tissue factor to activate the clotting cascade. Recent reports have shown rFVIIa may be a useful hemostatic agent in patients
Role of Recombinant Activated Factor VII in the Management of Life-threatening Coagulopathic Bleeding
Anaesthesia and Intensive Care ; Recombinant activated factor VII (rFVIIa, eptacog alfa, NovoSeven, NovoNordisk, Copenhagen, Denmark) appears to be an effective agent for the correction of a wide range of coagulopathies1. It has been available commercially in Australia since 1998, although at present it is approved by the
Use of recombinant factor VIIa for emergency reversal of anticoagulation
Journal of Postgraduate Medicine ; Anticoagulation for prevention and treatment of thromboembolism is achieved with the help of agents such as warfarin, acenocoumarol (coumarin), unfractionated heparin (UFH) and low molecular weight heparins (LMH). Patients on anticoagulation therapy may require rapid reversal of anticoagulation in
Dangerous remedy: Military doctors in Iraq say that Factor VII saves wounded soldiers, but other doctors and medical research suggest that it can cause fatal clots.
Baltimore Sun (Baltimore, MD) ; ... doing that. I hope so. robert.little@baltsun.com Copyright (c) 2006, The Baltimore Sun Distributed by McClatchy-Tribune Business News. For reprints, email tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write ...
The Use of Recombinant Activated Factor VII for Refractory Bleeding Post Complex Cardiothoracic Surgery
Anaesthesia and Intensive Care ; SUMMARY We reviewed the outcome following use of recombinant activated factor VII (rVIIa) in patients with major bleeding post cardiothoracic surgery in our unit between January 2002 and July 2004. The unit consists of 16 cardiothoracic intensive care beds in a public metropolitan teaching hospital
Use of Recombinant Factor VIIa for Adjunctive Hemorrhage Control in Trauma and Surgical Patients
The American Surgeon ; Recombinant factor VIIa (rFVIIa) has recently been described for patients with ongoing massive bleeding in a number of different clinical scenarios. A retrospective chart review was conducted at a public level I trauma center in order to describe the use of rFVIIa in trauma and surgical patients